

# Marburgvirus Infections Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Marburgvirus Infections

<https://marketpublishers.com/r/M823129F722EN.html>

Date: September 2018

Pages: 65

Price: US\$ 1,200.00 (Single User License)

ID: M823129F722EN

## Abstracts

Marburgvirus Infections Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Marburgvirus Infections Infection pipeline products.

### DISEASE OVERVIEW

Marburgvirus Infections infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as 'lockjaw' as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

## REPORT DESCRIPTION

The Marburgvirus Infections Infection pipeline guide presents complete overview of drugs currently being developed for Marburgvirus Infections Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Marburgvirus Infections Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Marburgvirus Infections Infection pipeline candidates is included.

Major companies participating in therapeutic development of Marburgvirus Infections Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Marburgvirus Infections Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Marburgvirus Infections Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Marburgvirus Infections Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

## SCOPE OF MARBURGVIRUS INFECTIONS INFECTION PIPELINE REPORT INCLUDES

Panorama of Marburgvirus Infections Infection pipeline markets including statistics on therapeutic drugs and companies involved

Marburgvirus Infections Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages

are covered

Marburgvirus Infections Infection pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Marburgvirus Infections Infection pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Marburgvirus Infections Infection pipeline therapeutics

## **REASONS TO BUY**

Get clear understanding of the entire Marburgvirus Infections Infection pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Marburgvirus Infections Infection pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

## Contents

### I. KEY FINDINGS

1. Companies Investing in Marburgvirus Infections Infection Pipeline include
  - Number of Companies with Marburgvirus Infections Infection projects in pre-clinical Development
  - Number of Companies with Marburgvirus Infections Infection projects in Clinical Development
  - Marburgvirus Infections Infection Pipeline Companies based in Americas
  - Marburgvirus Infections Infection Pipeline Companies based in Europe
  - Marburgvirus Infections Infection Pipeline Companies based in Asia Pacific
  - Marburgvirus Infections Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  - Marburgvirus Infections Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
  - Marburgvirus Infections Infection Pipeline Agents in Clinical Development stage
  - Marburgvirus Infections Infection Pipeline Therapeutic Compounds received special status
  - Mechanism of Action of most pipeline Drugs
  - Small molecules among the Marburgvirus Infections Infection Pipeline agents

### II. INSIGHTS INTO MARBURGVIRUS INFECTIONS INFECTION PIPELINE

1. Disease Overview
  - Introduction to Marburgvirus Infections Infection
  - Symptoms and Causes of Marburgvirus Infections Infection
  - Treatment or Prevention Options for Marburgvirus Infections Infection
  - Other Details
2. Phase wise Pipeline Compounds
  - Marburgvirus Infections Infection Pipeline Pre- Clinical/Discovery stage Drugs
  - Marburgvirus Infections Infection Pipeline Phase 1 stage Drugs
  - Marburgvirus Infections Infection Pipeline Phase 2 stage Drugs
  - Marburgvirus Infections Infection Pipeline Phase 3 stage Drugs
  - Marburgvirus Infections Infection Pipeline Pre-Registration stage Drugs
3. Company wise Marburgvirus Infections Infection Pipeline Compounds
4. Marburgvirus Infections Infection Pipeline by Mechanism of Action

### III. MARBURGVIRUS INFECTIONS INFECTION PIPELINE COMPOUND DETAILS

MVA-BN Filo multivalen  
BCX4430  
Pan filovirus  
filovirus vaccine  
Quinoxaline-based inhibitors of Ebola and Marburg VP40  
GEO-EM05  
trivalent Ebola-Marburg vaccine  
Marburg VLP Vaccine  
Bispecific Antibodies for Ebola and Marburg  
MBP091  
Small Molecules for Ebola/Marburg  
PBI-05204  
VesiculoVax monovalent vaccine  
VesiculoVax trivalent vaccine  
TargoVir

#### Drug Details

##### 1. Snapshot

Name of the Therapeutic Agent  
Originator  
Developing Company  
Co-Developer/License Partner  
Orphan Drug/Fast Track/Designation  
Development Phase

##### 2. Drug Overview

##### 3. Mechanism of Action

##### 4. Current Status

##### 5. Clinical Trial Details

## **IV. MARBURGVIRUS INFECTIONS INFECTION PIPELINE COMPANY BRIEFS**

Bavarian Nordic  
BioCryst Pharmaceuticals Inc  
Emergent BioSolutions Inc  
Emergex Vaccines  
Fox Chase Chemical Diversity Center Inc.  
GeoVax Labs Inc  
Greffex Inc  
Integrated BioTherapeutics Inc

Integrated BioTherapeutics Inc  
Mapp Biopharmaceutical Inc  
NanoViricides Inc  
Phoenix Biotechnology Inc  
Profectus BioSciences Inc  
Profectus BioSciences Inc  
Rodos BioTarget GmbH

## **V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MARBURGVIRUS INFECTIONS INFECTION PIPELINE MARKET**

### **VI. APPENDIX**

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

## I would like to order

Product name: Marburgvirus Infections Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Marburgvirus Infections

Product link: <https://marketpublishers.com/r/M823129F722EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M823129F722EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970